Analyst Price Target is $13.00
▲ +956.91% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Cardiff Oncology in the last 3 months. The average price target is $13.00, with a high forecast of $13.00 and a low forecast of $13.00. The average price target represents a 956.91% upside from the last price of $1.23.
Current Consensus is
The current consensus among 1 polled investment analysts is to buy stock in Cardiff Oncology. This Buy consensus rating has held steady for over two years.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and hematologic malignancies, such as KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. It primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.